At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 120 enrolled
Drug / intervention
TAS-114 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating TAS-114 and S-1 for Advanced Solid Tumors. Completed, enrolled 120 participants across 5 sites in 4 countries.
Detailed Summary
A Phase I, Open-Label, International, Multicenter, Non-Randomized, Dose-Escalating Safety, Tolerance and Pharmacokinetic Study of Oral Administration of TAS-114 in Combination with S-1 in a Twice Daily Schedule for 14 Days in Patients with Advanced Solid Tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesBelgium, France, Italy, Switzerland
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2013
First PostedMay 2015
Primary CompletionDec 2016
Study CompletionSep 2017
TodayJul 2026
First PostedMay 27, 2015
Enrollment StartMar 1, 2013
Primary CompletionDec 27, 2016
Study CompletionSep 30, 2017
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 11.1 years ago
Interventions
TAS-114drug
TAS-114 is an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism.
S-1drug
S-1 is an oral antimetabolite; a combination of three pharmacological compounds: tegafur (FT), gimeracil (CDHP), and oteracil (Oxo)